November 19, 2019 01:13 PM IST Earnings downgrade continued in the September quarter but there were no fresh negatives in terms of outlook in management commentaries.
January 11, 2019 05:07 PM IST Net Sales are expected to increase by 21.4 percent Y-o-Y (down 9.5 percent Q-o-Q) to Rs. 1019.5 crore, according to ICICI Direct.
October 17, 2018 06:17 PM IST Net Sales are expected to increase by 18.8 percent Y-o-Y (up 8.7 percent Q-o-Q) to Rs. 940 crore, according to HDFC Securities.
October 12, 2018 03:34 PM IST Net Sales are expected to increase by 20.7 percent Y-o-Y (up 10.4 percent Q-o-Q) to Rs. 952.3 crore, according to ICICI Direct.
April 23, 2018 03:27 PM IST Net Sales are expected to increase by 21.2 percent Y-o-Y (up 7 percent Q-o-Q) to Rs. 898.8 crore, according to KR Choksey.
April 20, 2018 01:40 PM IST Net Sales are expected to increase by 6.3 percent Y-o-Y (down 6.6 percent Q-o-Q) to Rs. 780 crore, according to HDFC Securities.
July 18, 2017 06:45 PM IST Net Sales are expected to decrease by 6.86 percent Q-o-Q (down 6.29 percent Y-o-Y) to Rs 689.5 crore, according to KR Choksey. Alembic Pharma to report net profit at 86.3 crore down 16.70% year-on-year.
April 17, 2017 01:04 PM IST Net Sales are expected to increase by 2.6 percent Q-o-Q (up 26.3 percent Y-o-Y) to Rs 791.1 crore, according to ICICI Securities. Alembic Pharma to report net profit at 71.3 crore up 66.6% quarter-on-quarter.
January 25, 2017 09:02 AM IST Alembic Pharmaceuticals is expected to show massive degrowth in third quarter earnings due to unfavourable base in year-ago quarter. Profit is likely to fall 60 percent year-on-year to Rs 107 crore and revenue may slip 14 percent to Rs 794 crore in Q3, according to average of estimates of analysts polled by CNBC-TV18.
January 17, 2017 04:22 PM IST Net Sales are expected to decrease by 9.5 percent Q-o-Q (down 14.2 percent Y-o-Y) to Rs 790 crore, according to HDFC Securities.
January 14, 2017 02:12 PM IST Net Sales are expected to decrease by 12.6 percent Q-o-Q (down 17.3 percent Y-o-Y) to Rs 762.3 crore, according to ICICI Securities.
January 13, 2017 12:28 PM IST Net Sales are expected to decrease by 18.4 percent Q-o-Q (down 22.1 percent Y-o-Y) to Rs 717.4 crore, according to KR Choksey.
July 29, 2016 02:35 PM IST Speaking to CNBC-TV18 Pranav Amin, Managing Director of Alembic Pharmaceuticals, said that good Q1 numbers were led by international business. Sales of its anti-psychotic drug Abilify was one of the reasons the company saw higher sales, he said.
February 04, 2015 03:14 PM IST In an interview with CNBC-TV18‘s Ekta Batra and Reema Tendulkar, Pranav Amin, Director & President- International Business, Alembic Pharmaceuticals, discussed the company‘s quarterly earnings.
October 20, 2014 04:08 PM IST The growth for the international generics, however, remain muted at about 9 percent due to higher base last year.
August 07, 2013 03:50 PM IST In an interview to CNBC-TV18, Amin adds that the company, despite the drug pricing policy, will grow at 15 percent.
May 06, 2013 01:33 PM IST Alembic Pharma is hopeful to increase operating margin by 100-120 basis points in current financial year on the back of strong growth in international and domestic generic business.
January 08, 2013 05:10 PM IST Angel Broking has come out with earning expectations for pharmaceutical sector for the October-December quarter of 2012. The research firm expects the Indian pharma sector to post lackluster numbers for 3QFY2013 on the sales front.
February 09, 2012 02:16 PM IST Alembic Pharma has announced its third quarter results. Pranav Amin, director of Alembic Pharma says, the revenues have gone up 15%, YoY. He further says, the company so far has filed 41 abbreviated new drug applications (ANDAs). “Over the next couple of years, we should see quite a bit of growth coming in international generic,” he adds.
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.
